News & articles

January 29, 2015 The MPD Research Consortium has just issued its most recent newsletter. This edition features updates on their clinical trials including several which are recruiting patients right now. Download the January edition now.

This research study is by QuintilesIMS (sponsored by Incyte Corporation)Background   QuintilesIMS Global Services, a worldwide consulting firm, is conducting a research study to better understand the experience of ET patients.  QuintilesIMS plans to interview patients who have been diagnosed with ET one‐on‐one over the phone. QuintilesIMS is looking for interested people to share what they have… Read More »SHARE YOUR EXPERIENCE WITH ESSENTIAL THROMBOCYTHEMIA (ET) TO HELP SHAPE THE FUTURE OF TREATMENT

By Raajit Rampal M.D. Ph.D., Assistant Attending Physician, Leukemia ServiceMemorial Sloan-Kettering Cancer Center The treatment of patients who have an MPN which evolves into an accelerated or blast-phase (greater than 10% or 20% blast-cells in the blood or bone marrow, respectively) remains a challenge. Patients with blast-phase or accelerated-phase disease are often treated with chemotherapy… Read More »PHASE 2 STUDY COMBINES RUXOLITINIB AND DECITABINE FOR PEOPLE WITH MPN

CTI BioPharma will start a new trial, PAC203 for MyelofibrosisBig news today on MPN drug development, as CTI BioPharma announces that the FDA has removed the full clinical hold they had placed on Pacritinib, a drug aimed at Myelofibrosis, in 2016. After the FDA placed Pacritinib on hold due to toxicity concerns, many MPN patients… Read More »PACRITINIB TAKEN OFF FDA CLINICAL HOLD

The MPN Research Foundation recognizes with sorrow the passing of Robert Tollen, who was one of the earliest voices in the MPN community through his online listserv https://sites.google.com/site/mpdsupport/.  Our condolences go to his family, and our thoughts are with the many patients whose lives he touched. To read his obituary and leave a comment for his… Read More »REMEMBERING ROBERT TOLLEN

Researchers Ann Mullally (prior MPNRF grantee) and Adam Mead have pubilshed in Blood about the development of MPN as it takes place in the hematopoeitic stem cell. Click here to read the abstract (full article requires purchase or login). They discuss how the mutant cells (JAK2, CALR, MPL) are dominant against normal cells.  Our understanding of the… Read More »MYELOPROLIFERATIVE NEOPLASM STEM CELLS: BLOOD ARTICLE BY ANN MULLALLY AND ADAM MEAD

FINAL ANALYSIS HAS CONCLUDED AT THIS TIME. PLEASE EMAIL wearempn@gmail.com FOR QUESTIONS OR COMMENTS of the following informaiton. A Message From The Mayo Clinic: Greetings to our myeloproliferative neoplasm (MPN) patients and dear friends! We would like to tell you a little about one of our new research projects and invite you to participate.  Patients with types… Read More »NUTRIENT TRIAL RECRUITING MPN PATIENTS

We are now accepting proposals for MPN Challenge™ grants. Click here to read the full RFP. Click here to access the application. Proposals are due April 3, 2017.  Each year we focus on a different element of MPN research. In the past this has included stopping or reversing fibrosis, mechanisms of action of interferon, preclinical JAK2 work,… Read More »2017 REQUEST FOR PROPOSALS

June 13, 2017 UT San Antonio makes Dr. Ruben Mesa head of their Cancer Center. Dr. Mesa was Deputy Director of the Mayo Clinic Cancer Center and will be moving on as Director at UT Health San Antonio starting this August. The MPN community looks forward to the great work you will continue at UT Health Cancer Center.      See link… Read More »CONGRATULATIONS TO DR. MESA ON HIS EXCITING MOVE

AOP Orphan and PharmEssentia announced its latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera  On June 25, 2017 at the 22nd Congress of European Hematology Association (EHA) conference held in Spain, AOP Orphan Pharmaceuticals AG of Austria and Taipei, Taiwan headquartered PharmEssentia announced the latest results from three of their clinical studies on Ropeginterferon… Read More »BREAKING NEWS ON P1101